A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03110822 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Ruxolitinib Oral Tablet [Jakafi]
DRUG: Lenalidomide
DRUG: Methylprednisolone

Sponsor

Oncotherapeutics

Collaborators

[object Object]